Starlix
Starlix Price range: $ 40,00 through $ 288,00
Back to products
Stromectol
Stromectol Price range: $ 50,00 through $ 1 000,00

Strattera

Price range: $ 40,00 through $ 500,00

Strattera is an effective non-stimulant medication specifically designed to manage the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in both children and adults. As a selective norepinephrine reuptake inhibitor, it works by balancing natural chemicals in the brain to improve overall cognitive function and mental clarity. Patients using this treatment often experience a significant increase in their ability to pay attention, stay focused on complex tasks, and reduce impulsive behaviors. This medication provides a steady, long-term solution for individuals looking to control hyperactivity and maintain composure throughout their daily routine. By offering consistent symptom relief, Strattera supports better organization and enhanced productivity in both professional and academic environments.

Active substance: Atomoxetine
SKU: Strattera Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Strattera belongs to a class of medications designated as selective norepinephrine reuptake inhibitors. It is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric patients 6 years of age and older, adolescents, and adults. Unlike traditional pharmacological treatments for ADHD, this prescription medication is not classified as a central nervous system stimulant.

The active ingredient in Strattera is atomoxetine hydrochloride, which target molecular mechanisms in the brain to help improve symptoms of inattention, impulsivity, and hyperactivity. In accordance with federal regulations in the United States, Strattera is available strictly by prescription (Rx) from a licensed healthcare provider and must be used as part of a total treatment program.

Parameter Details
Active ingredient Atomoxetine hydrochloride
Therapeutic class Selective norepinephrine reuptake inhibitor (SNRI)
Dosage form Oral capsules (10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg)
Route of administration Oral
Primary purpose Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
Prescription status Prescription only (Rx)

Prescription Information and Clinical Overview

What it’s used for

Strattera is FDA-approved for the management of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 and older, adolescents, and adults. Diagnostic criteria for ADHD require the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and were present before age 12. A comprehensive treatment plan typically encompasses psychological, educational, and social interventions in addition to pharmacotherapy. The efficacy of Strattera was established in double-blind, placebo-controlled clinical trials across pediatric and adult populations. Any application of this medication outside of FDA-approved ADHD management is considered off-label and requires distinct clinical justification by a qualified prescriber.

How the drug works

The precise therapeutic mechanism of atomoxetine in ADHD is not completely elucidated, but it is primarily attributed to selective inhibition of the presynaptic norepinephrine transporter. By blocking the reuptake of norepinephrine, atomoxetine increases extracellular levels of this neurotransmitter in synaptic spaces within the central nervous system, particularly in the prefrontal cortex. The prefrontal cortex is an area of the brain associated with executive function, attention control, and impulse regulation. Atomoxetine demonstrates high selectivity for the norepinephrine transporter and exhibits minimal binding affinity for other neurotransmitter receptors, including dopamine, histamine, or cholinergic receptors.

Dosing schedule

Strattera is administered orally as a single daily dose in the morning or as two evenly divided doses in the morning and late afternoon. Capsules must be swallowed whole and not opened, crushed, or chewed. For pediatric patients weighing up to 70 kg, the initial recommended daily dose is approximately 0.5 mg/kg, which is increased after a minimum of 3 days to a target daily dose of approximately 1.2 mg/kg. For pediatric patients weighing over 70 kg and adults, initiation starts at 40 mg daily, titrated after a minimum of 3 days to a target dose of 80 mg daily. The maximum recommended total daily dose is 100 mg. Dose adjustments are required in patients with hepatic impairment or those concurrently taking strong CYP2D6 inhibitors.

What happens in the body

Atomoxetine is rapidly absorbed after oral administration, reaching peak plasma concentration (Cmax) within 1 to 2 hours. Absolute bioavailability ranges between 63% and 94%, influenced by individual hepatic metabolism. Food intake does not clinically alter the extent of absorption. Atomoxetine is extensively metabolized in the liver primarily via the cytochrome P450 2D6 (CYP2D6) enzymatic pathway into 4-hydroxyatomoxetine. In extensive CYP2D6 metabolizers, the plasma elimination half-life is approximately 5 hours. In poor CYP2D6 metabolizers, clearance is significantly lower, resulting in higher drug exposure and an extended elimination half-life of approximately 24 hours. The drug is predominantly excreted via urine as glucuronide metabolites.

Compatibility with other medicines

Co-administration of Strattera with monoamine oxidase inhibitors (MAOIs) is strictly contraindicated due to the potential risk of severe, potentially fatal reactions including hyperthermia, myoclonus, autonomic instability, and agitation. At least 14 days must elapse between stopping an MAOI and starting atomoxetine. Strong CYP2D6 inhibitor drugs–such as fluoxetine, paroxetine, or quinidine–substantially increase systemic exposure to atomoxetine, requiring dosage adjustment. Caution is warranted when combining atomoxetine with pressor agents or antihypertensive medications, as well as systemic or inhaled beta-2 agonists like albuterol, due to possible additive effects on heart rate and blood pressure.

Adverse reactions

In pediatric clinical trials, the most commonly reported adverse events included severe abdominal pain, nausea, vomiting, decreased appetite, fatigue, somnolence, and irritability. In adult clinical trials, reported side effects included dry mouth, nausea, constipation, decreased appetite, insomnia, erectile dysfunction, urinary hesitation, and dysmenorrhea. Increases in blood pressure and heart rate have been observed across all age groups. Most adverse reactions are mild to moderate in severity and may resolve over time, but persistent or severe reactions require immediate consultation with the prescribing physician.

Important precautions

Strattera carries a boxed warning regarding an increased risk of suicidal ideation in children and adolescents. Patients initiating therapy should be monitored closely for clinical worsening, suicidality, or unusual behavioral changes, particularly during the initial months of therapy or following dose adjustments. Postmarketing reports have documented rare instances of severe liver injury progressing to acute liver failure; treatment must be discontinued in patients with jaundice or laboratory evidence of hepatic dysfunction. Atomoxetine should be used with caution in patients with hypertension, tachycardia, or cardiovascular disorders. In pediatric patients, regular monitoring of height and weight is indicated to track growth velocity.

Red flags

Certain clinical signs mandate immediate emergency medical evaluation. Patients or caregivers should seek emergency care if symptoms of severe hypersensitivity occur, such as angioedema of the face, lips, throat, or tongue, or severe urticaria. Emergency consultation is required upon the appearance of signs of hepatic injury, including yellowing of the eyes or skin (jaundice), dark urine, or upper right abdominal tenderness. Sudden severe cardiovascular symptoms–such as chest pain, shortness of breath, sudden palpitations, or syncope–demand immediate evaluation. Immediate psychiatric attention is necessary if a patient exhibits suicidal thoughts, acute psychotic symptoms, or extreme aggression.

Emergency Symptom (Red Flag) Recommended Immediate Action
Swelling of face, lips, tongue, or throat Seek immediate emergency medical attention (Call 911)
Yellowing skin or eyes (jaundice), dark urine Discontinue medication and seek urgent medical evaluation
Chest pain, fainting, or severe palpitations Seek immediate emergency medical evaluation
New or worsening suicidal thoughts or behaviors Contact emergency psychiatric services immediately
Painful or prolonged erection (priapism) Seek immediate emergency medical care

If you skip a dose

If a dose of Strattera is missed, it should be taken as soon as remembered on the same day. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the normal dosing schedule resumed. Patients must not administer extra capsules or double the dose to make up for a missed application. If multiple daily doses are missed consecutively, the prescribing physician should be consulted to determine whether re-titration is necessary before restarting treatment.

Day-to-day use

Strattera should be taken consistently at the same time each day to maintain stable plasma concentrations. Taking the capsule with meals may reduce initial gastrointestinal adverse effects such as nausea or abdominal discomfort. Capsules should not be opened or divided because atomoxetine powder is a strong ocular irritant. If powder contacts the eyes, they must be flushed immediately with water. Patients should exercise caution when operating hazardous machinery or driving until they determine how atomoxetine affects their mental alertness and physical coordination.

Storage and expiration

Strattera capsules should be stored at controlled room temperature, between 20°C and 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C (59°F to 86°F). Keep the bottle tightly closed in its original packaging to protect the contents from excessive light and moisture. Avoid storing the medication in humid places such as bathrooms. Store out of the reach and sight of children and domestic animals. Expired or unneeded medication should be disposed of in accordance with local pharmaceutical disposal guidelines or community take-back programs.

Frequently Asked Questions

How long does it take for Strattera to show full clinical efficacy?

Unlike stimulant medications that often demonstrate rapid onset of action, atomoxetine typically requires continuous daily administration over several weeks to reach peak therapeutic efficacy. Initial improvements in ADHD symptoms may be observed within 1 to 2 weeks of starting treatment, but full clinical effects are generally evaluated after 4 to 6 weeks of continuous daily use. Adherence to the prescribed dosing schedule is essential during this titration period.

Is Strattera classified as a controlled substance in the United States?

No, atomoxetine is not a controlled substance under federal law in the United States and is not scheduled by the Drug Enforcement Administration (DEA). Clinical studies showed no evidence of abuse potential or physical dependence associated with atomoxetine. However, it remains a prescription-only (Rx) medication that requires clinical evaluation and authorization by a licensed healthcare provider.

Can Strattera capsules be opened and mixed with food or liquids?

No, Strattera capsules must be swallowed whole and should never be opened, crushed, or chewed. Atomoxetine hydrochloride acts as an ocular irritant, and opening the capsule creates a risk of eye exposure. If an opened capsule accidentally contacts the eyes, flush immediately with water and contact a healthcare provider. Patients who experience difficulty swallowing capsules should discuss management options with their physician.

What routine monitoring is required during long-term atomoxetine therapy?

Healthcare providers typically monitor blood pressure and heart rate prior to initiation and at regular intervals during treatment. In pediatric populations, growth metrics including weight and height are monitored routinely. Physicians may also order laboratory evaluations of liver function if clinical indicators of hepatic stress arise, alongside ongoing monitoring for behavioral or mood changes.

Information on this page is for reference and does not replace an assessment by a licensed healthcare professional. In accordance with FDA regulations.

Additional information
Dosage

10mg

,

18mg

,

25mg

,

40mg

Package

10 pills

,

20 pills

,

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία